

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02607)

**UPDATE ON THE CONNECTED TRANSACTION
COMPLETION OF THE ACQUISITION OF 10% EQUITY INTEREST IN FINANCE
COMPANY**

We refer to the announcements of Shanghai Pharmaceuticals Holding Co., Ltd.* (the “**Company**”) dated 26 July 2025 and 9 September 2025 (the “**Announcements**”), in relation to the Company’s acquisition of 10% equity interest in Finance Company from SIIC Dongtan (the “**Acquisition**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company is pleased to announce that on 12 January 2026, the Acquisition was completed on the principal terms and conditions of the Share Transfer Agreement as disclosed in the Announcements. As of the date of this announcement, Finance Company was held as to 40% by the Company.

By order of the Board

Shanghai Pharmaceuticals Holding Co., Ltd.*

YANG Qiuhua

Chairman

Shanghai, the PRC, 14 January 2026

As of the date of this announcement, the executive Directors of the Company are Mr. YANG Qiuhua, Mr. SHEN Bo, Mr. LI Yongzhong and Mr. DONG Ming; the non-executive Director is Mr. ZHANG Wenxue; and the independent non-executive Directors are Mr. GU Zhaoyang, Mr. FOK Manson, Mr. WANG Zhong and Ms. MAN Kwan.

** For identification purpose only*